SHR-9839 + almonertinib

**SHR-9839 + almonertinib** is an investigational combination therapy evaluated for the treatment of advanced solid tumors. SHR-9839 is a novel agent whose detailed molecular mechanism or class is currently unclear from public sources, and almonertinib (HS-10296) is a third-generation, irreversible, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to target both EGFR-sensitizing and T790M resistance mutations in non–small cell lung cancer (NSCLC)[1][2][4][6]. This combination leverages the antitumor activity and resistance-overcoming potential of almonertinib; the rationale for SHR-9839 within multidrug regimens is to potentially enhance therapeutic efficacy or overcome additional mechanisms of resistance[1].

Other names

SHR-9839SHR9839SHR 9839HS-10296HS10296HS 10296